263 related articles for article (PubMed ID: 30798508)
1. Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects.
Wang Z; Wu J; Tian X; Hao C
Front Med; 2019 Aug; 13(4):427-437. PubMed ID: 30798508
[TBL] [Abstract][Full Text] [Related]
2. Desmoid-type fibromatosis: toward a holistic management.
Penel N; Kasper B; van Der Graaf WTA
Curr Opin Oncol; 2021 Jul; 33(4):309-314. PubMed ID: 33973549
[TBL] [Abstract][Full Text] [Related]
3. Current management and recent progress in desmoid tumors.
Zhou MY; Bui NQ; Charville GW; Ghanouni P; Ganjoo KN
Cancer Treat Res Commun; 2022; 31():100562. PubMed ID: 35460976
[TBL] [Abstract][Full Text] [Related]
4. Desmoid-type fibromatosis: Current therapeutic strategies and future perspectives.
Ibrahim R; Assi T; Khoury R; Ngo C; Faron M; Verret B; Lévy A; Honoré C; Hénon C; Le Péchoux C; Bahleda R; Le Cesne A
Cancer Treat Rev; 2024 Feb; 123():102675. PubMed ID: 38159438
[TBL] [Abstract][Full Text] [Related]
5. Medical treatment of mammary desmoid-type fibromatosis: which benefit?
Scheer L; Lodi M; Molière S; Kurtz JE; Mathelin C
World J Surg Oncol; 2017 Apr; 15(1):86. PubMed ID: 28420393
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Physician's Systemic Treatment Preferences for Patients with Advanced Desmoid-Type Fibromatosis: Experience-Based Medicine in the Absence of High-Level Evidence.
Schöffski P; Requilé A; van Cann T
Oncol Res Treat; 2018; 41(4):214-219. PubMed ID: 29562221
[TBL] [Abstract][Full Text] [Related]
7. The Activity and Safety of Anlotinib for Patients with Extremity Desmoid Fibromatosis: A Retrospective Study in a Single Institution.
Zheng C; Zhou Y; Wang Y; Luo Y; Tu C; Min L
Drug Des Devel Ther; 2020; 14():3941-3950. PubMed ID: 33061299
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of apatinib for patients with advanced extremity desmoid fibromatosis: a retrospective study.
Zheng C; Fang J; Wang Y; Zhou Y; Tu C; Min L
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2127-2135. PubMed ID: 33452581
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of gamma-secretase inhibitor nirogacestat (PF-03084014) in desmoid tumor: Report of four pediatric/young adult cases.
Takahashi T; Prensner JR; Robson CD; Janeway KA; Weigel BJ
Pediatr Blood Cancer; 2020 Oct; 67(10):e28636. PubMed ID: 32762028
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor.
Villalobos VM; Hall F; Jimeno A; Gore L; Kern K; Cesari R; Huang B; Schowinsky JT; Blatchford PJ; Hoffner B; Elias A; Messersmith W
Ann Surg Oncol; 2018 Mar; 25(3):768-775. PubMed ID: 28887726
[TBL] [Abstract][Full Text] [Related]
11. Activity of the Gamma Secretase Inhibitor AL101 in Desmoid Tumors: A Case Report of 2 Adult Cases.
Chan D; Kaplan J; Gordon G; Desai J
Curr Oncol; 2021 Sep; 28(5):3659-3667. PubMed ID: 34590610
[TBL] [Abstract][Full Text] [Related]
12. Systemic treatment approaches for sporadic desmoid-type fibromatosis: scarce evidence and recommendations.
Kasper B
Oncol Res Treat; 2015; 38(5):244-8. PubMed ID: 25896775
[TBL] [Abstract][Full Text] [Related]
13. New treatments for desmoid tumors.
Kasper B
Curr Opin Oncol; 2023 Jul; 35(4):292-295. PubMed ID: 37222208
[TBL] [Abstract][Full Text] [Related]
14. The Notch signaling pathway in desmoid tumor: Recent advances and the therapeutic prospects.
Zheng C; Huang J; Xu G; Li W; Weng X; Zhang S
Biochim Biophys Acta Mol Basis Dis; 2024 Jan; 1870(1):166907. PubMed ID: 37793461
[TBL] [Abstract][Full Text] [Related]
15. Management of serious complications in intra-abdominal desmoid-type fibromatosis.
Bini F; Fiore M; Provenzano S; Bertulli R; Ottini A; Colombo C; Vitellaro M; Greco G; Morosi C; Gronchi A; Casali PG; Palassini E
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1411. PubMed ID: 34165246
[TBL] [Abstract][Full Text] [Related]
16. Desmoid-type fibromatosis of the head and neck in children: A changing situation.
Paul A; Blouin MJ; Minard-Colin V; Galmiche L; Coulomb A; Corradini N; Boutroux H; Van den Abbeele T; Leboulanger N; Denoyelle F; Garabedian EN; Couloigner V; Orbach D
Int J Pediatr Otorhinolaryngol; 2019 Aug; 123():33-37. PubMed ID: 31059930
[TBL] [Abstract][Full Text] [Related]
17. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG).
Kasper B; Baumgarten C; Garcia J; Bonvalot S; Haas R; Haller F; Hohenberger P; Penel N; Messiou C; van der Graaf WT; Gronchi A;
Ann Oncol; 2017 Oct; 28(10):2399-2408. PubMed ID: 28961825
[TBL] [Abstract][Full Text] [Related]
18. Desmoid Fibromatosis: Management in an Era of Increasing Options.
Ratan R; Roland CL; Bishop AJ
Curr Oncol Rep; 2021 Mar; 23(4):41. PubMed ID: 33719012
[TBL] [Abstract][Full Text] [Related]
19. Desmoid fibromatosis: MRI features of response to systemic therapy.
Sheth PJ; Del Moral S; Wilky BA; Trent JC; Cohen J; Rosenberg AE; Temple HT; Subhawong TK
Skeletal Radiol; 2016 Oct; 45(10):1365-73. PubMed ID: 27502790
[TBL] [Abstract][Full Text] [Related]
20. Desmoid-Type Fibromatosis: Evolving Treatment Standards.
Fiore M; MacNeill A; Gronchi A; Colombo C
Surg Oncol Clin N Am; 2016 Oct; 25(4):803-26. PubMed ID: 27591500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]